Omicron covid vaccines may avoid protection provided by antibody therapies: study

Washington: Omicron Can avoid the immune defenses provided by Covid-19 vaccines And natural infections, according to a peer-reviewed study, also suggest that the new strain of coronavirus is completely resistant to the antibody therapies used today.
The study, published Thursday in the journal Nature, also highlights the need for new vaccines and treatments that predict how SARS-CoV-2 virus May be developed soon.
Researchers at Columbia University in the U.S. and the University of Hong Kong noted that an attractive feature of Omicron is the alarming number of variations in variant spike proteins that could pose a risk to the effectiveness of current vaccines and Therapeutic antibodies.
The study tested the potency of antibodies produced by vaccination to neutralize omikron in laboratory tests that contain antibodies against live viruses and against pseudoviruses built into the lab to mimic variants.
The researchers found that people’s antibodies were vaccinated twice with Moderna. Pfizer, AstraZeneca, and Johnson & Johnson Covid-19 vaccines were significantly less effective in inactivating Omicron than the original virus.
Antibodies to previously infected individuals were less likely to neutralize Omicron, they said.
People who have received booster shots of the Pfizer or Moderna vaccine are more likely to be protected, although their antibodies also exhibit less neutralizing activity against Omicron, studies show.
“New results indicate that previously infected individuals and fully vaccinated individuals are at risk of infection with the Omicron variant,” said David Hoe, a professor at Columbia University’s Vegalos College of Physicians and Surgeons.
Hoe added, “Even a third booster shot may not adequately protect against Omicron infection, but of course it is advisable to get it, as you will still get some immunity benefits,” Hoe added.
The researchers noted that the findings were consistent with other inactivation studies, as well as preliminary epidemiological data from South Africa and the UK, which showed that the effectiveness of two doses of the vaccine against symptomatic disease was significantly reduced against omicron.
Studies also suggest that all monoclonal antibody treatments currently in use and most in development are much less effective against omikron.
Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful pathogens, such as viruses.
In a study of neutralization with monoclonal antibodies, only one – BRI 198 approved in China – maintains significant activity against omikron, according to the researchers.
A small form of Omicron is completely resistant to all antibodies in clinical use today, they said.
The authors of the study note that Omicron is now the most complete “escape” from deactivation that scientists have seen.
They also identified four new mutations in Omicron’s spike protein that help protect the virus from antibodies, a discovery that could signal the formation of new approaches to coping with variants.
The SARS-CoV-2 virus uses spike proteins to enter and infect human cells.
Researchers suggest that new vaccines and treatments need to be developed that can better predict how the virus is evolving.
“It is not far-fetched to think that SARS-CoV-2 is only one or two mutations from being completely resistant to current antibodies, either monoclonal antibodies used as a treatment or antibodies produced by vaccination or antibodies produced by infection with previous variations. Hoe added.


Source link

Leave a Comment